Constellation Pharmaceuticals

78 articles about Constellation Pharmaceuticals

• MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology

  7/15/2021

  MorphoSys AG announced the successful completion of its previously announced cash tender offer for all outstanding shares of Constellation Pharmaceuticals, Inc. for $34.00 per share, net to the seller in cash, without interest and subject to any applicable withholding of taxes.

• MorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals

  7/1/2021

  MorphoSys AG today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended for its tender offer for Constellation Pharmaceuticals, Inc.

• Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib

  6/11/2021

  Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), today announced that three posters relating to the MANIFEST clinical trial of pelabresib (CPI-0610) in myelofibrosis (MF) were published online in association with the European Hematology Association (EHA) annual meeting.

• Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting

  6/4/2021

  Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today summarized in a poster presentation preliminary data from the ongoing Phase 1/2 trial of CPI-0209

• MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma

  6/2/2021

  MorphoSys AG (FSE:MOR) announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion.

• MorphoSys to Acquire Constellation Pharmaceuticals

  6/2/2021

  Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in Hematology-Oncology and Expands into Solid Tumors Best-in-Class Combined Discovery and Development Capabilities Accelerates Ability to Provide New Cancer Treatments to Patients MorphoSys Enters into Strategic Funding Partnership with Royalty Pharma

• 

  MorphoSys Pharma's Double Deal: Buys Constellation and Enters Partnership with Royalty Pharma

  6/2/2021

  MorphoSys Pharma is acquiring Constellation Pharmaceuticals for about $1.7 billion. Here's everything you need to know about this billion dollars deal.

• Constellation Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference - May 31, 2021

  5/31/2021

  Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced that the Company will participate in an upcoming virtual investor conference.

• Constellation Pharmaceuticals Announces First-Quarter 2021 Financial Results and Provides Business Update

  5/10/2021

  Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced its first-quarter 2021 financial results.

• Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2021 Results

  4/27/2021

  Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on May 10, 2021, to discuss its first quarter 2021 results and provide a business update.

• Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2020 Financial Results

  2/24/2021

  Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its fourth-quarter 2020 financial results and provided a business update.

• Constellation Pharmaceuticals to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

  2/19/2021

  Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual investor conference.

• Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 Results

  2/18/2021

  Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on February 24, 2021, to discuss its fourth quarter 2020 results and provide a business update

• Constellation Pharmaceuticals Appoints Brendan Delaney as Chief Commercial Officer

  1/7/2021

  Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief Commercial Officer, effective January 11, 2021.

• Constellation Pharmaceuticals Presents at J.P. Morgan Healthcare Conference

  1/6/2021

  CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Jigar Raythatha, CEO, will present a company overview at the J.P. Morgan Healthcare Conference at 10:50 AM EST on Thursday, January 14, 2021. A live audio webcast of the presentation and archive for replay will be available on the Investor Relations section of Constellation’s website at  http://ir.constellationpharma.com/events-and-presentations/events . The audio webca

• 

  Constellation Announces Promising Results for Investigational Myelofibrosis Therapy

  12/7/2020

  Constellation Pharmaceuticals announced on Sunday that it has received preliminary data from its Phase II MANIFEST and Phase III MANIFEST-2 clinical trials involving CPI-0610 for myelofibrosis.

• Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting

  12/6/2020

  67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeks

• Constellation Pharmaceuticals to Host Analyst / Investor Event to Discuss Update of MANIFEST Clinical Trial for CPI-0610 Presented at ASH Meeting

  11/23/2020

  Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a virtual analyst/investor event and conference call on December 7 at 8:00 AM EDT to discuss the data from two oral presentations and two posters on the MANIFEST clinical trial for CPI-0610 being presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

• Constellation Pharmaceuticals Announces Third-Quarter 2020 Financial Results

  10/29/2020

  Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced its third-quarter 2020 financial results.

• Constellation Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

  9/9/2020

  Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in upcoming virtual investor conferences